Beta Drugs's Total Assets for the quarter that ended in Mar. 2026 was ₹4,958 Mil.
During the past 12 months, Beta Drugs's average Total Assets Growth Rate was 22.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 25.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 27.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 35.30% per year.
During the past 13 years, Beta Drugs's highest 3-Year average Total Assets Growth Rate was 157.60%. The lowest was 20.70%. And the median was 41.70%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Beta Drugs's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Beta Drugs Total Assets Related Terms
Beta Drugs Total Assets Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Beta Drugs's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Total Assets of ₹4,958 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Total Assets too high?
Beta Drugs' current Total Assets is ₹4,958 Mil. Overall, Beta Drugs has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Total Assets compare to ZTS and UTHR?
Beta Drugs' Total Assets of ₹4,958 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Beta Drugs and its competitors. Beta Drugs's current Total Assets is ₹4,958 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,971.70, compared to a current price of ₹2,153.40 — trading 9.2% above its estimated fair value. The current Total Assets is ₹4,958 Mil. Beta Drugs' overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Total Assets is ₹4,958 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,153.40 is trading 9.2% above its estimated GF Value™ of ₹1,971.70.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
Total Assets: ₹4,958 Mil
GF Value™: ₹1,971.70 vs. price of ₹2,153.40 (9.2% above fair value)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
88GF Score
Get the complete analysis for NSE:BETA
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
